Talasaz AmirAli, Co-Chief Executive Officer of Guardant Health (GH), has demonstrated a consistent pattern of selling activity in the company’s stock, with no recorded purchases across 26 transactions totaling $16.5 million in sales. The bulk of these sales occurred in concentrated clusters, most notably on December 8, 2025, when AmirAli sold shares worth $5.25 million across three transactions, followed by another $5.09 million in sales on July 1, 2025. More recently, on March 13, 2026, he disposed of shares valued at $1.17 million, continuing a trend of periodic divestments. Smaller but notable sales include a $761,949 transaction on October 1, 2025, and a $198,172 sale on January 1, 2026.
The filings indicate that AmirAli’s transactions are primarily tied to stock option exercises (coded "F") and outright sales (coded "S"), with no offsetting buys. The absence of any acquisition activity suggests a one-directional approach to reducing his position in GH. While the sales are spread across multiple dates, the largest disposals align with mid-to-late 2025, followed by a smaller but steady continuation into early 2026. The consistency of these transactions, without any counterbalancing purchases, underscores a clear disposition toward trimming his stake in Guardant Health over time.
AI-assisted summary